Pacira BioSciences

NASDAQ: PCRX ↗$36.31 USD$1.65B (pending Viatris acquisition) MCAP

#Non-Opioid Pain Management #Postsurgical Pain #Osteoarthritis #Regenerative Health

Pacira BioSciences is a specialty pharmaceutical company focused on the development, manufacture and commercialization of non-opioid pain management and regenerative health solutions. Its commercial portfolio includes EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain, and the iovera system, a handheld cryoanalgesia device. On October 8, 2026, Viatris agreed to acquire Pacira for $36.50 per share in cash in a transaction valued at approximately $1.65 billion.

Company Info

Sector:Specialty Pharmaceuticals / Non-Opioid Pain Management

Headquarters:Brisbane, California, United States

Founded:2006

Website:www.pacira.com/

Upcoming Milestones & Key Dates

2026-10-08

Corporate / M&A

Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash (~$1.65B)

Clinical Development Pipeline

EXPAREL (bupivacaine liposome injectable suspension)

Target: Long-acting local analgesic

Postsurgical pain management

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ZILRETTA (triamcinolone acetonide ER)

Target: Extended-release intra-articular corticosteroid

Osteoarthritis knee pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

iovera system

Target: Handheld cryoanalgesia device

Targeted peripheral nerve pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PCRX-201

Target: Gene therapy vector platform

Osteoarthritis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Frank D. Lee

Chief Executive Officer

Shawn M. Cross

Chief Financial Officer

Dr. Jonathan Slonin, M.D.

Chief Medical Officer

Careers & Job Openings

See all open roles

All departments

See posting

Apply Now →